1Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiologic Rev,1993,15:466-485.
2Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nature Genetics,2002 ,31: 395-399.
3Lung ML, Sham JST, Lam WP, et al. Analysis of Epstein-Barr virus in localized nasopharyngeal carcinoma tumors.Cancer,1993,71:1190-1192.
4Burgos JS, Vera-Sempere FJ. Analysis of EBV latency by EBER in situ hybridization in nasopharyngeal carcinoma Spanish patients. Anticancer Res,2001,21:3921-3 924.
5Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst,2002,94:1614-1619.
6Abdulkarim B, Sabri S, Zelenika D, et al. Antiviral agenycidoforir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radio sensitivity in EBV -ratated malignancies. Oncogene,2003,22:2260-2271.
8Chan KH, Gu YL, Ng F,et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer,2003,105:706-70 9.
9Liu MT, Yeh CY. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Radiat Med,1998,16:113-117.
10Ho S, Teo P, Kwan WH, et al. Staging and IgA VCA titer in patients with nasopharyngeal carcinoma: changes over a 12-year period. Oral Oncol,1998,34:491-495 .
2Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein Barr virus DNA in serum of patients with nasopharyngeal carcinoma[J]. Clin Cancer Res,1998,4(3):665-669.
3Lo Y M, Chan L Y, Lo K W, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with naso pharyngeal carcinoma[J]. Cancer Res, 1999,59(6): 1188-1191.
4Yap Y Y, Hassan S, Chan M, et al. Epstein-Barr virus DNA detection in the diagnosis of nasopharyngeal earcinoma[J]. Otolaryngol Head Neck Surg, 2007,136(6):986-91.
6Chan K C, Zhang J, Chan A T, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients [J]. Cancer Res, 2003, 63(9):2028-2032.
7Twu C W, Wang W Y, Liang W M, et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2007,67(1) :130-137.
8Lo Y M, Leung S F, Chan L Y, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma[J]. Cancer Res, 2000, 60(9) :2351-2355.
9Kalpoe J S, Dekker P B, van Krieken J H, et al. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area[J]. J Clin Pathol, 2006,59(5):537-541.
